MX2019013717A - Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia. - Google Patents
Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia.Info
- Publication number
- MX2019013717A MX2019013717A MX2019013717A MX2019013717A MX2019013717A MX 2019013717 A MX2019013717 A MX 2019013717A MX 2019013717 A MX2019013717 A MX 2019013717A MX 2019013717 A MX2019013717 A MX 2019013717A MX 2019013717 A MX2019013717 A MX 2019013717A
- Authority
- MX
- Mexico
- Prior art keywords
- dementia
- cognitive impairment
- subject
- humans
- fractions
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title abstract 6
- 208000010877 cognitive disease Diseases 0.000 title abstract 6
- 208000028698 Cognitive impairment Diseases 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 206010012289 Dementia Diseases 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000009514 concussion Effects 0.000 abstract 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente solicitud se refiere a la administración de plasma, fracciones del mismo o mezclas del mismo a seres humanos o animales para el tratamiento o mejorar de otro modo los trastornos del deterioro cognitivo, que incluyen demencia (por ejemplo, demencia vascular, demencia con cuerpos de Lewy, demencia resultante de la enfermedad de Alzheimer, demencia resultante de la enfermedad de Parkinson, demencia frontotemporai y demencia resultante de hidrocefalia de presión normal en seres humanos y síndrome de disfunción cognitiva en animales de compañía), conmoción cerebral y lesión cerebral por traumatismo. En determinadas modalidades, la invención comprende un método para tratar un trastorno del deterioro cognitivo en un sujeto humano o animal de compañía, dicho método comprende: aplicar a dicho sujeto una o más pruebas de funcionamiento cognitivo para identificar a un sujeto que padezca de un trastorno del deterioro cognitivo; y administrar a dicho sujeto una cantidad terapéuticamente eficaz de una composición de plasma de origen animal; en donde dicha administración proporciona una mejora en los resuitados de dichos sujetos en una o más pruebas del deterioro cognitivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201730705A ES2690178A1 (es) | 2017-05-18 | 2017-05-18 | Plasma de animal o fracciones del mismo para su utilización en el tratamiento de trastornos de deterioro cognitivo en seres humanos y animales de compañia |
| PCT/EP2018/062915 WO2018211014A1 (en) | 2017-05-18 | 2018-05-17 | Animal plasma or fractions thereof for use in treating cognitive impairment disorders in humans and companion animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019013717A true MX2019013717A (es) | 2020-09-10 |
Family
ID=62217967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013717A MX2019013717A (es) | 2017-05-18 | 2018-05-17 | Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11690871B2 (es) |
| EP (1) | EP3624813A1 (es) |
| JP (1) | JP7312163B2 (es) |
| CA (1) | CA3063792A1 (es) |
| ES (1) | ES2690178A1 (es) |
| MX (1) | MX2019013717A (es) |
| WO (1) | WO2018211014A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024084400A2 (en) * | 2022-10-17 | 2024-04-25 | Bio Immunitas Ltd. | Alpha 2 macroglobulin, soluble klotho and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030099635A1 (en) | 2001-10-04 | 2003-05-29 | Protein Therapeutics, Inc. | Use of oral gammaglobulin for the treatment of immune-mediated diseases |
| GB0305133D0 (en) | 2003-03-06 | 2003-04-09 | Sinvent As | Product |
| GB0508153D0 (en) * | 2005-04-22 | 2005-06-01 | Aimsco Ltd | Therapeutic agent |
| EP2149380A1 (en) * | 2008-07-29 | 2010-02-03 | Medivet Pharma, S.L. | Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction. |
| BR112016012968A2 (pt) * | 2013-12-09 | 2017-08-08 | Univ Leland Stanford Junior | Métodos e composições para o tratamento de condições associadas com o envelhecimento |
| US10130657B2 (en) * | 2015-02-13 | 2018-11-20 | John C. Hughes | Formulation, apparatus, and methods for treatment of brain trauma |
| CN106511378B (zh) * | 2016-12-29 | 2018-07-20 | 北京豪思生物科技有限公司 | 一种用于增强记忆力的血浆提取物及其制备方法和应用 |
-
2017
- 2017-05-18 ES ES201730705A patent/ES2690178A1/es not_active Withdrawn
-
2018
- 2018-05-17 CA CA3063792A patent/CA3063792A1/en active Pending
- 2018-05-17 EP EP18726114.4A patent/EP3624813A1/en active Pending
- 2018-05-17 US US16/613,951 patent/US11690871B2/en active Active
- 2018-05-17 MX MX2019013717A patent/MX2019013717A/es unknown
- 2018-05-17 JP JP2020514338A patent/JP7312163B2/ja active Active
- 2018-05-17 WO PCT/EP2018/062915 patent/WO2018211014A1/en active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| CA3063792A1 (en) | 2018-11-22 |
| US11690871B2 (en) | 2023-07-04 |
| JP7312163B2 (ja) | 2023-07-20 |
| US20210260112A1 (en) | 2021-08-26 |
| EP3624813A1 (en) | 2020-03-25 |
| ES2690178A1 (es) | 2018-11-19 |
| JP2020520387A (ja) | 2020-07-09 |
| WO2018211014A1 (en) | 2018-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008368A (es) | Uso de antagonista de il-33 o un antagonista de il-4r en la fabricacion de un medicamento para tratar enfermedades o trastornos inflamatorios. | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| EP4001277A3 (en) | Bicyclic compounds for diagnosis and therapy | |
| MX2019010994A (es) | Metodos para tratar enfermedades y trastornos mediados por el complemento. | |
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| ZA202001057B (en) | Inhibiting ubiquitin specific peptidase 30 | |
| GEP20227446B (en) | New catecholamine prodrugs for use in treatment of parkinson's disease | |
| MX2017010544A (es) | Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo. | |
| EA201991375A1 (ru) | Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| EP3810135A4 (en) | ENHANCED DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| IL282562A (en) | Composition and use for the treatment of parkinson's disease and related disorders | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| EP4252755A3 (en) | Therapeutic compounds | |
| EP4285993A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| WO2019075456A3 (en) | Methods and substances for prevention and treatment of neurodegenerative diseases | |
| BR112021018591A2 (pt) | Compostos e usos dos mesmos | |
| WO2008157747A8 (en) | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders | |
| CA2864606C (en) | Methods of treating and preventing diseases and disorders of the central nervous system | |
| MX2020001855A (es) | Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides. | |
| PH12020551179A1 (en) | Methods for treating mitochondrial disorder |